PUBLISHER: The Business Research Company | PRODUCT CODE: 1957354
PUBLISHER: The Business Research Company | PRODUCT CODE: 1957354
Isocitrate Dehydrogenase (IDH) Inhibitors Global Market Report 2026
Isocitrate dehydrogenase (IDH) inhibitors are a class of targeted cancer therapies designed to block the activity of mutated IDH1 and IDH2 enzymes. These enzymes play a role in cellular metabolism, and mutations can lead to abnormal cell growth and cancer development.
The main types of IDH inhibitors include those targeting IDH1 mutant medullary malignant tumors, IDH2 mutant medullary malignant tumors, and others. IDH1 mutant medullary malignant tumors are cancers that arise in the central (medullary) part of an organ or tissue and are associated with mutations in the IDH1 gene. Treatment involves molecules such as monoclonal antibodies, peptides, small molecules, and others, administered via oral, parenteral, subcutaneous, or topical routes. They are applied in therapies including FLT3 inhibitors, DH inhibitors, hedgehog pathway inhibitors, and related treatments.
Tariffs have impacted the IDH inhibitors market by increasing the cost of specialty APIs, oncology-grade excipients, and advanced drug-delivery materials. Oral and parenteral targeted therapies for AML, glioma, and cholangiocarcinoma are most affected, particularly in North America and Europe due to dependence on imported oncology drug ingredients. Hospitals and specialty oncology centers face higher therapy costs. However, tariffs are encouraging local synthesis of small-molecule oncology drugs and strengthening regional pharmaceutical research and manufacturing capacity.
The isocitrate dehydrogenase (idh) inhibitors market research report is one of a series of new reports from The Business Research Company that provides isocitrate dehydrogenase (idh) inhibitors market statistics, including isocitrate dehydrogenase (idh) inhibitors industry global market size, regional shares, competitors with a isocitrate dehydrogenase (idh) inhibitors market share, detailed isocitrate dehydrogenase (idh) inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the isocitrate dehydrogenase (idh) inhibitors industry. This isocitrate dehydrogenase (idh) inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The isocitrate dehydrogenase (idh) inhibitors market size has grown exponentially in recent years. It will grow from $2.46 billion in 2025 to $3.13 billion in 2026 at a compound annual growth rate (CAGR) of 26.8%. The growth in the historic period can be attributed to cancer genomics research, unmet oncology needs, mutation-driven drug discovery, hospital oncology adoption, clinical trial expansion.
The isocitrate dehydrogenase (idh) inhibitors market size is expected to see exponential growth in the next few years. It will grow to $8.02 billion in 2030 at a compound annual growth rate (CAGR) of 26.6%. The growth in the forecast period can be attributed to precision medicine advancement, biomarker-driven oncology care, rare cancer drug pipelines, combination cancer therapies, regulatory support for targeted drugs. Major trends in the forecast period include expansion of targeted oncology therapies, increased genetic mutation-based drug development, growing focus on rare cancer treatment, rising use of precision oncology diagnostics, advancement of small molecule cancer inhibitors.
The rising incidence of acute myeloid leukemia (AML) is expected to drive growth in the isocitrate dehydrogenase (IDH) inhibitors market in the coming years. AML is a fast-growing blood and bone marrow cancer characterized by the rapid production of abnormal white blood cells that interfere with normal blood cell formation. The increasing occurrence of AML is largely due to the aging population, as older adults are at higher risk of developing this aggressive blood cancer because of age-related changes in bone marrow and immune function. IDH inhibitors help treat AML by blocking mutant IDH enzymes, which restores normal blood cell development and slows the proliferation of leukemia cells. For example, according to the Leukaemia Foundation in February 2023, between 2022 and 2035, over 7,000 children, 6,000 young adults, and 108,000 adults aged 25-65 are expected to be diagnosed with blood cancers, primarily acute lymphoblastic leukemia (ALL), AML, and non-Hodgkin lymphoma (NHL). As a result, the rising frequency of AML is expected to drive growth in the IDH inhibitors market.
Leading companies in the IDH inhibitors market are focusing on securing regulatory approvals to expand clinical use, accelerate market entry, and gain a competitive edge in treating IDH-mutant cancers. Regulatory approvals are official permissions granted by health authorities that allow a drug to be marketed and used after its safety and efficacy have been confirmed. For instance, in August 2024, Servier Laboratoires, a France-based pharmaceutical company, received FDA approval for VORANIGO (vorasidenib) tablets as the first targeted therapy for patients with Grade 2 IDH-mutant glioma, including astrocytoma and oligodendroglioma with IDH1 or IDH2 mutations. This oral treatment significantly improved progression-free survival, as demonstrated in the Phase 3 INDIGO trial, where patients had a median progression-free survival of 27.7 months compared to 11.1 months for placebo. VORANIGO provides a convenient, well-tolerated treatment option with manageable side effects, representing a major advance for patients with limited prior therapies.
In November 2025, Amoy Diagnostics Co. Ltd., a China-based healthcare technology company, partnered with Servier to expand precision oncology and genetic testing solutions. Through this collaboration, Amoy Diagnostics and Servier aim to enhance cancer and rare disease diagnostics by combining Amoy's molecular assays with Servier's clinical genomics and therapeutic expertise. The partnership seeks to deliver faster, more accurate, and widely accessible testing, improve data interpretation, streamline laboratory workflows, and increase patient access to personalized medicine. Servier is a France-based healthcare technology company specializing in the development and commercialization of innovative therapeutics and diagnostic solutions across oncology, cardiology, and rare diseases.
Major companies operating in the isocitrate dehydrogenase (idh) inhibitors market are Roche Holding AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Daiichi Sankyo Company Limited, Les Laboratoires Servier, Evotec SE, HUTCHMED (China) Limited, Rigel Pharmaceuticals Inc., CStone Pharmaceuticals, Forma Therapeutics Holdings Inc., Philogen S.p.A., Kura Oncology Inc., Agios Pharmaceuticals Inc., Adooq Bioscience LLC, Taiho Pharmaceutical Co. Ltd., Celgene Corporation, Focus Biomolecules LLC, InvivoChem LLC
North America was the largest region in the isocitrate dehydrogenase (IDH) inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the isocitrate dehydrogenase (idh) inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the isocitrate dehydrogenase (idh) inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The isocitrate dehydrogenase (IDH) inhibitors market consists of sales of selective IDH1 inhibitors, selective IDH2 inhibitors, dual IDH1/IDH2 inhibitors, combination therapies, and delivery forms. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods, such as formulation development, packaging, and regulatory support.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Isocitrate Dehydrogenase (IDH) Inhibitors Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses isocitrate dehydrogenase (idh) inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for isocitrate dehydrogenase (idh) inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The isocitrate dehydrogenase (idh) inhibitors market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Scope
- Markets Covered:1) By Type: IDH1 Mutant Medullary Malignant Tumor; IDH2 Mutant Medullary Malignant Tumor; Other Types
- 2) By Molecule Type: Monoclonal Antibodies; Peptides; Small Molecules; Other Molecule Types
- 3) By Route Of Administration: Oral; Parenteral; Subcutaneous; Topical
- 4) By Application: FLT3 Inhibitor; DH Inhibitor; Hedgehog Pathway Inhibitor; Other Applications
- Subsegments:
- 1) By IDH1 Mutant Medullary Malignant Tumor: Acute Myeloid Leukemia (AML); Glioma Or Glioblastoma; Cholangiocarcinoma; Chondrosarcoma
- 2) By IDH2 Mutant Medullary Malignant Tumor: Acute Myeloid Leukemia (AML); Myelodysplastic Syndromes (MDS); Angioimmunoblastic T-Cell Lymphoma (AITL)
- 3) By Other Types: Solid Tumors With IDH Mutations; Metastatic Cancers With IDH Alterations; Experimental Or Off-Label Uses In Rare Cancers
- Companies Mentioned: Roche Holding AG; Merck & Co. Inc.; Bristol-Myers Squibb Company; Novartis AG; GlaxoSmithKline plc; Eli Lilly and Company; Daiichi Sankyo Company Limited; Les Laboratoires Servier; Evotec SE; HUTCHMED (China) Limited; Rigel Pharmaceuticals Inc.; CStone Pharmaceuticals; Forma Therapeutics Holdings Inc.; Philogen S.p.A.; Kura Oncology Inc.; Agios Pharmaceuticals Inc.; Adooq Bioscience LLC; Taiho Pharmaceutical Co. Ltd.; Celgene Corporation; Focus Biomolecules LLC; InvivoChem LLC
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
- Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time Series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: Word, PDF or Interactive Report
- + Excel Dashboard
- Added Benefits
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.
Table of Contents
1. Executive Summary
- 1.1. Key Market Insights (2020-2035)
- 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
- 1.3. Major Factors Driving the Market
- 1.4. Top Three Trends Shaping the Market
2. Isocitrate Dehydrogenase (IDH) Inhibitors Market Characteristics
- 2.1. Market Definition & Scope
- 2.2. Market Segmentations
- 2.3. Overview of Key Products and Services
- 2.4. Global Isocitrate Dehydrogenase (IDH) Inhibitors Market Attractiveness Scoring And Analysis
- 2.4.1. Overview of Market Attractiveness Framework
- 2.4.2. Quantitative Scoring Methodology
- 2.4.3. Factor-Wise Evaluation
- Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
- 2.4.4. Market Attractiveness Scoring and Interpretation
- 2.4.5. Strategic Implications and Recommendations
3. Isocitrate Dehydrogenase (IDH) Inhibitors Market Supply Chain Analysis
- 3.1. Overview of the Supply Chain and Ecosystem
- 3.2. List Of Key Raw Materials, Resources & Suppliers
- 3.3. List Of Major Distributors and Channel Partners
- 3.4. List Of Major End Users
4. Global Isocitrate Dehydrogenase (IDH) Inhibitors Market Trends And Strategies
- 4.1. Key Technologies & Future Trends
- 4.1.1 Biotechnology, Genomics & Precision Medicine
- 4.1.2 Artificial Intelligence & Autonomous Intelligence
- 4.1.3 Industry 4.0 & Intelligent Manufacturing
- 4.1.4 Digitalization, Cloud, Big Data & Cybersecurity
- 4.1.5 Sustainability, Climate Tech & Circular Economy
- 4.2. Major Trends
- 4.2.1 Expansion Of Targeted Oncology Therapies
- 4.2.2 Increased Genetic Mutation-Based Drug Development
- 4.2.3 Growing Focus On Rare Cancer Treatment
- 4.2.4 Rising Use Of Precision Oncology Diagnostics
- 4.2.5 Advancement Of Small Molecule Cancer Inhibitors
5. Isocitrate Dehydrogenase (IDH) Inhibitors Market Analysis Of End Use Industries
- 5.1 Hospitals
- 5.2 Oncology Clinics
- 5.3 Cancer Research Centers
- 5.4 Specialty Clinics
- 5.5 Academic Medical Centers
6. Isocitrate Dehydrogenase (IDH) Inhibitors Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market
7. Global Isocitrate Dehydrogenase (IDH) Inhibitors Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
- 7.1. Global Isocitrate Dehydrogenase (IDH) Inhibitors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 7.2. Global Isocitrate Dehydrogenase (IDH) Inhibitors Market Size, Comparisons And Growth Rate Analysis
- 7.3. Global Isocitrate Dehydrogenase (IDH) Inhibitors Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
- 7.4. Global Isocitrate Dehydrogenase (IDH) Inhibitors Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)
8. Global Isocitrate Dehydrogenase (IDH) Inhibitors Total Addressable Market (TAM) Analysis for the Market
- 8.1. Definition and Scope of Total Addressable Market (TAM)
- 8.2. Methodology and Assumptions
- 8.3. Global Total Addressable Market (TAM) Estimation
- 8.4. TAM vs. Current Market Size Analysis
- 8.5. Strategic Insights and Growth Opportunities from TAM Analysis
9. Isocitrate Dehydrogenase (IDH) Inhibitors Market Segmentation
- 9.1. Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- IDH1 Mutant Medullary Malignant Tumor, IDH2 Mutant Medullary Malignant Tumor, Other Types
- 9.2. Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Monoclonal Antibodies, Peptides, Small Molecules, Other Molecule Types
- 9.3. Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Oral, Parenteral, Subcutaneous, Topical
- 9.4. Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- FLT3 Inhibitor, DH Inhibitor, Hedgehog Pathway Inhibitor, Other Applications
- 9.5. Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Sub-Segmentation Of IDH1 Mutant Medullary Malignant Tumor, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Acute Myeloid Leukemia (AML), Glioma Or Glioblastoma, Cholangiocarcinoma, Chondrosarcoma
- 9.6. Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Sub-Segmentation Of IDH2 Mutant Medullary Malignant Tumor, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Angioimmunoblastic T-Cell Lymphoma (AITL)
- 9.7. Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Solid Tumors With IDH Mutations, Metastatic Cancers With IDH Alterations, Experimental Or Off-Label Uses In Rare Cancers
10. Isocitrate Dehydrogenase (IDH) Inhibitors Market Regional And Country Analysis
- 10.1. Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- 10.2. Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
11. Asia-Pacific Isocitrate Dehydrogenase (IDH) Inhibitors Market
- 11.1. Asia-Pacific Isocitrate Dehydrogenase (IDH) Inhibitors Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 11.2. Asia-Pacific Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Segmentation By Molecule Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
12. China Isocitrate Dehydrogenase (IDH) Inhibitors Market
- 12.1. China Isocitrate Dehydrogenase (IDH) Inhibitors Market Overview
- Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 12.2. China Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Segmentation By Molecule Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
13. India Isocitrate Dehydrogenase (IDH) Inhibitors Market
- 13.1. India Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Segmentation By Molecule Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
14. Japan Isocitrate Dehydrogenase (IDH) Inhibitors Market
- 14.1. Japan Isocitrate Dehydrogenase (IDH) Inhibitors Market Overview
- Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 14.2. Japan Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Segmentation By Molecule Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
15. Australia Isocitrate Dehydrogenase (IDH) Inhibitors Market
- 15.1. Australia Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Segmentation By Molecule Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
16. Indonesia Isocitrate Dehydrogenase (IDH) Inhibitors Market
- 16.1. Indonesia Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Segmentation By Molecule Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
17. South Korea Isocitrate Dehydrogenase (IDH) Inhibitors Market
- 17.1. South Korea Isocitrate Dehydrogenase (IDH) Inhibitors Market Overview
- Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 17.2. South Korea Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Segmentation By Molecule Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
18. Taiwan Isocitrate Dehydrogenase (IDH) Inhibitors Market
- 18.1. Taiwan Isocitrate Dehydrogenase (IDH) Inhibitors Market Overview
- Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 18.2. Taiwan Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Segmentation By Molecule Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
19. South East Asia Isocitrate Dehydrogenase (IDH) Inhibitors Market
- 19.1. South East Asia Isocitrate Dehydrogenase (IDH) Inhibitors Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 19.2. South East Asia Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Segmentation By Molecule Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
20. Western Europe Isocitrate Dehydrogenase (IDH) Inhibitors Market
- 20.1. Western Europe Isocitrate Dehydrogenase (IDH) Inhibitors Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 20.2. Western Europe Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Segmentation By Molecule Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
21. UK Isocitrate Dehydrogenase (IDH) Inhibitors Market
- 21.1. UK Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Segmentation By Molecule Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
22. Germany Isocitrate Dehydrogenase (IDH) Inhibitors Market
- 22.1. Germany Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Segmentation By Molecule Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
23. France Isocitrate Dehydrogenase (IDH) Inhibitors Market
- 23.1. France Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Segmentation By Molecule Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
24. Italy Isocitrate Dehydrogenase (IDH) Inhibitors Market
- 24.1. Italy Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Segmentation By Molecule Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
25. Spain Isocitrate Dehydrogenase (IDH) Inhibitors Market
- 25.1. Spain Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Segmentation By Molecule Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
26. Eastern Europe Isocitrate Dehydrogenase (IDH) Inhibitors Market
- 26.1. Eastern Europe Isocitrate Dehydrogenase (IDH) Inhibitors Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 26.2. Eastern Europe Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Segmentation By Molecule Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
27. Russia Isocitrate Dehydrogenase (IDH) Inhibitors Market
- 27.1. Russia Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Segmentation By Molecule Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
28. North America Isocitrate Dehydrogenase (IDH) Inhibitors Market
- 28.1. North America Isocitrate Dehydrogenase (IDH) Inhibitors Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 28.2. North America Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Segmentation By Molecule Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
29. USA Isocitrate Dehydrogenase (IDH) Inhibitors Market
- 29.1. USA Isocitrate Dehydrogenase (IDH) Inhibitors Market Overview
- Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 29.2. USA Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Segmentation By Molecule Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
30. Canada Isocitrate Dehydrogenase (IDH) Inhibitors Market
- 30.1. Canada Isocitrate Dehydrogenase (IDH) Inhibitors Market Overview
- Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 30.2. Canada Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Segmentation By Molecule Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
31. South America Isocitrate Dehydrogenase (IDH) Inhibitors Market
- 31.1. South America Isocitrate Dehydrogenase (IDH) Inhibitors Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 31.2. South America Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Segmentation By Molecule Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
32. Brazil Isocitrate Dehydrogenase (IDH) Inhibitors Market
- 32.1. Brazil Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Segmentation By Molecule Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
33. Middle East Isocitrate Dehydrogenase (IDH) Inhibitors Market
- 33.1. Middle East Isocitrate Dehydrogenase (IDH) Inhibitors Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 33.2. Middle East Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Segmentation By Molecule Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
34. Africa Isocitrate Dehydrogenase (IDH) Inhibitors Market
- 34.1. Africa Isocitrate Dehydrogenase (IDH) Inhibitors Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 34.2. Africa Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Segmentation By Molecule Type, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
35. Isocitrate Dehydrogenase (IDH) Inhibitors Market Regulatory and Investment Landscape
36. Isocitrate Dehydrogenase (IDH) Inhibitors Market Competitive Landscape And Company Profiles
- 36.1. Isocitrate Dehydrogenase (IDH) Inhibitors Market Competitive Landscape And Market Share 2024
- 36.1.1. Top 10 Companies (Ranked by revenue/share)
- 36.2. Isocitrate Dehydrogenase (IDH) Inhibitors Market - Company Scoring Matrix
- 36.2.1. Market Revenues
- 36.2.2. Product Innovation Score
- 36.2.3. Brand Recognition
- 36.3. Isocitrate Dehydrogenase (IDH) Inhibitors Market Company Profiles
- 36.3.1. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
- 36.3.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.3. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
- 36.3.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 36.3.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
37. Isocitrate Dehydrogenase (IDH) Inhibitors Market Other Major And Innovative Companies
- Eli Lilly and Company, Daiichi Sankyo Company Limited, Les Laboratoires Servier, Evotec SE, HUTCHMED (China) Limited, Rigel Pharmaceuticals Inc., CStone Pharmaceuticals, Forma Therapeutics Holdings Inc., Philogen S.p.A., Kura Oncology Inc., Agios Pharmaceuticals Inc., Adooq Bioscience LLC, Taiho Pharmaceutical Co. Ltd., Celgene Corporation, Focus Biomolecules LLC
38. Global Isocitrate Dehydrogenase (IDH) Inhibitors Market Competitive Benchmarking And Dashboard
39. Key Mergers And Acquisitions In The Isocitrate Dehydrogenase (IDH) Inhibitors Market
40. Isocitrate Dehydrogenase (IDH) Inhibitors Market High Potential Countries, Segments and Strategies
- 40.1 Isocitrate Dehydrogenase (IDH) Inhibitors Market In 2030 - Countries Offering Most New Opportunities
- 40.2 Isocitrate Dehydrogenase (IDH) Inhibitors Market In 2030 - Segments Offering Most New Opportunities
- 40.3 Isocitrate Dehydrogenase (IDH) Inhibitors Market In 2030 - Growth Strategies
- 40.3.1 Market Trend Based Strategies
- 40.3.2 Competitor Strategies
41. Appendix
- 41.1. Abbreviations
- 41.2. Currencies
- 41.3. Historic And Forecast Inflation Rates
- 41.4. Research Inquiries
- 41.5. The Business Research Company
- 41.6. Copyright And Disclaimer
